Success Metrics

Clinical Success Rate

88.5%

Based on 23 completed trials

Completion Rate

88%(23/26)

Active Trials

0(0%)

Results Posted

17%(4 trials)

Terminated

3(9%)

Phase Distribution

Ph early_phase_1

Ph not_applicable

44%

Ph phase_4

13%

Ph phase_3

13%

Ph phase_1

13%

Ph phase_2

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution32 total trials

Early Phase 1First-in-human

3(9.4%)

Phase 1Safety & dosage

4(12.5%)

Phase 2Efficacy & side effects

3(9.4%)

Phase 3Large-scale testing

4(12.5%)

Phase 4Post-market surveillance

4(12.5%)

N/ANon-phased studies

14(43.8%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

82.1%

23 of 28 finished

Non-Completion Rate

17.9%

5 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(1)

Completed(23)

Terminated(5)

Other(3)

Detailed Status

Completed23

Terminated3

unknown3

Withdrawn2

Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

88.5%

Most Advanced

Phase 4

Trials by Phase

Early Phase 13 (9.4%)

Phase 14 (12.5%)

Phase 23 (9.4%)

Phase 34 (12.5%)

Phase 44 (12.5%)

N/A14 (43.8%)

Trials by Status

terminated39%

completed2372%

not_yet_recruiting13%

withdrawn26%

unknown39%

Recent Activity

0 active trials

Showing 5 of 32

not_yet_recruitingnot_applicable

Age Comparisons of Exercising Muscle O2 Supply in Healthy Adults: Effects of Esmolol Infusion

NCT04181606

completednot_applicable

Blocking of the Gut Hormone Receptor for Glucagon-like Peptide 2 (GLP-2) by the GLP-2 Receptor Antagonist GLP-2(3-33)

NCT06774807

View all 32 trials

Clinical Trials (32)

Showing 20 of 32 trialsScroll for more

NCT07118592Not Applicable

Genetic Architecture of Natriuretic Peptides and Blood Pressure Response

Not Yet Recruiting

NCT04740736Not Applicable

Cardiovascular Analysis of PEM

Completed

NCT02692313Early Phase 1

Dose Response of Epinephrine

Completed

NCT04181606Early Phase 1

Age Comparisons of Exercising Muscle O2 Supply in Healthy Adults: Effects of Esmolol Infusion

Completed

NCT06774807Not Applicable

Blocking of the Gut Hormone Receptor for Glucagon-like Peptide 2 (GLP-2) by the GLP-2 Receptor Antagonist GLP-2(3-33)

Completed

NCT02098629Phase 2

Concomitant Milrinone and Esmolol Treatment in Patients with Acute Myocardial Infarction

Completed

NCT01151605Not Applicable

The Suppression of Toll Like Receptors by Insulin

Completed

NCT02592824Phase 3

Glutamate for Metabolic Intervention in Coronary Surgery II

Completed

NCT04140396Phase 4

Continuous Intravenous Lidocaine Infusion Versus Placebo for Rib Fracture Analgesia

Terminated

NCT05683444Early Phase 1

Octreotide Improves Human Lymphatic Fluid Transport a Translational Trial

Completed

NCT05289440Not Applicable

Esketamine Administration on Recovery Quality After Radical Mastectomy

Completed

NCT03646474Not Applicable

Single Dose Tranexamic Acid in Reducing Blood Loss During Cytoreductive Surgery and HIPEC

Completed

NCT03809923Not Applicable

Dexmedetomidine Combined With Lidocaine Infusion Affect PONV

Completed

NCT04706767Not Applicable

Effect of Co-administration Lidocaine and Dexmedetomidine on Quality of Recovery

Completed

NCT03571919Phase 4

Lidocaine Infusions for Rib Fractures

Withdrawn

NCT02219321Phase 3

Lidocaine Infusion for Chronic Pain in Opioid Dependent Patients

Terminated

NCT02997800Phase 2

The Effect of Intraoperative Labetalol on Time to Discharge

Completed

NCT03657537Phase 1

Effects of Ketone Bodies on Cognition in Type 2 Diabetes

Completed

NCT02425202Phase 4

Ketamine Infusion for Pediatric Patients With Obstructive Sleep Apnea Syndrome (OSAS) After Tonsillectomy

Completed

NCT02910765Phase 4

Methylene Blue and Ozone in Early Sepsis

Unknown

Drug Details

Intervention Type: DIETARY SUPPLEMENT
Total Trials: 32